Your browser doesn't support javascript.
loading
Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.
Xu, B; Sun, T; Zhang, Q; Zhang, P; Yuan, Z; Jiang, Z; Wang, X; Cui, S; Teng, Y; Hu, X-C; Yang, J; Pan, H; Tong, Z; Li, H; Yao, Q; Wang, Y; Yin, Y; Sun, P; Zheng, H; Cheng, J; Lu, J; Zhang, B; Geng, C; Liu, J; Shen, K; Yu, S; Li, H; Tang, L; Qiu, R.
Afiliación
  • Xu B; Department of Medical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; State Key Laboratory of Molecular Oncology, National Cancer Centre/Cancer Hospital, Chinese Acade
  • Sun T; Department of Internal Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
  • Zhang Q; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Zhang P; Department of Medical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Yuan Z; Department of Medical Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Jiang Z; Department of Breast Cancer, The Fifth Medical Cent, Chinese PLA General Hospital, Beijing, China.
  • Wang X; Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Cui S; Breast Cancer Centre, Henan Cancer Hospital, Zhengzhou, China.
  • Teng Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
  • Hu XC; Department of Medical Oncology, Fudan University Cancer Center, Shanghai, China.
  • Yang J; Department of Medical Oncology, The PLA General Hospital, Beijing, China.
  • Pan H; Department of Medical Oncology, Sir Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Tong Z; Department of Breast Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China.
  • Li H; Department of Breast Oncology, Peking University Cancer Hospital, Beijing, China.
  • Yao Q; Department of Medical Oncology, Nankai University Tianjing People's Hospital, Tianjing, China.
  • Wang Y; Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
  • Yin Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Sun P; Department of Oncology, Qingdao University Yantai Yuhuangding Hospital, Yantai, China.
  • Zheng H; Department of Medical Oncology, Sichuan University West China Hospital, Chengdu, China.
  • Cheng J; Department of Oncology, Tongji Medical College Wuhan Union Hospital, Wuhan, China.
  • Lu J; Department of Breast Surgery, Shanghai Jiaotong University Renji Hospital, Shanghai, China.
  • Zhang B; Department of Medical Oncology, Nantong Tumor Hospital, Nantong, China.
  • Geng C; Department of Breast Oncology, Hebei Medical University Tumor Hospital, Shijiazhuang, China.
  • Liu J; Department of Medical Oncology, Fujian Medical University Cancer Hospital, Fuzhou, China.
  • Shen K; Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Yu S; Cancer Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
  • Li H; Department of Breast Surgery, Sichuan Cancer Hospital, Chengdu, China.
  • Tang L; Department of Research and Development, Beijing Biostar Technologies, Beijing, China.
  • Qiu R; Department of Research and Development, Beijing Biostar Technologies, Beijing, China.
Ann Oncol ; 32(2): 218-228, 2021 02.
Article en En | MEDLINE | ID: mdl-33188874
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Antraciclinas Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Antraciclinas Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article